KDT 501

Drug Profile

KDT 501

Alternative Names: KDT501

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KinDex Pharmaceuticals
  • Class Anti-inflammatories; Antihyperglycaemics; Cyclopentanes; Insulin sensitisers; Small molecules
  • Mechanism of Action GPR120 protein stimulants; Inflammasome modulators; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Non-alcoholic steatohepatitis
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 06 Sep 2017 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
  • 06 Sep 2017 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) (KinDex Pharmaceuticals pipeline, September 2017)
  • 30 Sep 2015 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top